HURA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
TuHURA Biosciences Inc (HURA) is not a strong buy for a beginner investor with a long-term focus at this moment. Despite bullish technical indicators and a favorable analyst rating, the company's weak financial performance, lack of significant positive catalysts, and absence of recent trading signals suggest that it is better to hold off on investing until clearer growth trends emerge.
The technical indicators show a bullish trend with MACD above 0 and positively contracting, RSI in the neutral zone, and moving averages in a bullish alignment (SMA_5 > SMA_20 > SMA_200). However, the stock's pre-market and regular market changes indicate recent downward pressure.
Rodman & Renshaw initiated coverage with a Buy rating and a $7 price target, citing the potential of TuHURA's immuno-oncology technologies.
The company's financial performance in Q4 2025 was weak, with a significant drop in net income (-66.97% YoY) and EPS (-88.18% YoY). Additionally, there are no recent news or significant trading trends from insiders or hedge funds.
In Q4 2025, revenue remained at 0 with no growth, net income dropped significantly to -$6,763,405 (-66.97% YoY), and EPS fell to -0.13 (-88.18% YoY). Gross margin also remained at 0 with no improvement.
Rodman & Renshaw initiated coverage with a Buy rating and a $7 price target, based on the valuation of TuHURA's immuno-oncology technologies.
